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LETTER TO THE EDITOR
Lopinavir/ritonavir- and indinavir-induced throm-
bocytopenia in a patient with HIV infection
Thrombocytopenia is observed in approximately
40% of people with HIV infection, of which 40%
show it as a ﬁrst symptom of infection.1,2 Two
types of thrombocytopenia may occur: primary au-
toimmune HIV-associated thrombocytopenia (the
most common cause), and secondary thrombocy-
topenia (for example caused by an intercurrent
infection or a drug reaction).1,2 When a patient
with HIV-associated autoimmune thrombocytope-
nia begins highly active antiretroviral treatment
(HAART) the thrombocytopenia often disappears.3,4
Moreover, during structured treatment inter-
ruption, recurring thrombocytopenia associated
with the interruption of antiretroviral therapy
has been reported.5 Occasionally even severe
HIV-associated thrombocytopenia may persist de-
spite antiretroviral treatment.6 On the other hand,
antiretrovirals themselves may cause thrombocy-
topenia. This has been reported with zidovudine,7
saquinavir,7 indinavir,7—10 lamivudine,7 stavudine7
and nevirapine.7 A patient with thrombocytopenia
induced by a protease inhibitor (initially indinavir
and later lopinavir/ritonavir) is described here.
A 46-year-old HIV positive woman with a previ-
ous history of IV drug abuse was admitted to the
hospital in March 1999 due to fever and HIV-related
encephalopathy. Physical examination showed a
thin and anaemic woman with a temperature of
38 ◦C. She presented with oral candidiasis and fa-
cial seborrheic dermatitis. No pathogens were de-
tected by blood, bone marrow or urine cultures. A
CT scan of the brain showed cerebral atrophy. Bio-
logical and radiological work-up did not reveal any
cancer. Laboratory tests showed the following re-
sults: haemoglobin 6.4 g/dl, white blood cell count
3 × 109/l, platelet count 95 × 109/l, red blood
cells 2.88 × 1012/l, moderate anisocytosis and mi-
crocytosis, normal renal function, LDH 1951U/l,
AST 654U/l, ALT 25U/l. A bone marrow biopsy
showed a normal cellular bone marrow with a mat-
uration abnormality of red and white blood cells
and platelets, moderate plasmocytosis and a slight
degree of reticulin ﬁbrosis. Her CD4+ lymphocyte
count was very low at 23/l, and her viral load
very high at 750,000 copies/ml.
Six units of packed cells were administered. Dif-
ferent antiretroviral drugs had been prescribed in
the past including lamivudine, zidovudine and in-
dinavir but she had never been adherent to these
treatment regimens.
During hospitalisation, lamivudine, stavudine
and indinavir treatment was started. One week
later her thrombocyte count decreased to 16 ×
109/l. All antivirals were stopped and her throm-
bocyte count increased to 53 × 109/l. After a
rechallenge with indinavir, lamivudine and stavu-
dine her thrombocyte count decreased again to
15 × 109/l. She received a thrombocyte trans-
fusion and gammaglobulins, and was discharged
on a nelﬁnavir, saquinavir, lamivudine and stavu-
dine regimen. Again, she was not adherent to this
treatment. In February 2001, because of a per-
sistent high viral load, antiretroviral therapy with
stavudine, abacavir and lopinavir/ritonavir was ini-
tiated. Her thrombocyte count at that time was
69× 109/l, dropping two weeks later to 7 × 109/l.
The lopinavir/ritonavir was then switched to nevi-
rapine. Her thrombocyte count increased up to 190
× 109/l. Her viral load was then 127,000 copies/ml
plasma but her thrombocyte count dropped again
to 24 × 109/l in April 2002 during a rechallenge
with lopinavir/ritonavir. Her viral load was then
7960 copies/ml plasma. When lopinavir/ritonavir
was replaced by efavirenz, the thrombocyte count
rose again to 126 × 109/l. In December 2002 her
CD4+ lymphocyte count was 40/l and her viral
load 635,000 copies/ml plasma. Genotypic resis-
tance testing showed resistance to non-nucleoside
reverse transcriptase inhibitors. Therefore she was
started again on lopinavir/ritonavir together with
lamivudine and tenofovir. In March 2003, just be-
fore switching to lopinavir/ritonavir, her thrombo-
cyte count was 79 × 109/l. Three weeks later her
thrombocyte count dropped to 18 × 109/l. When
epistaxis occurred all antiretrovirals were stopped
and she received gammaglobulins intravenously.
When the thrombocyte level returned to normal
she was switched to a HAART regimen including
atazanavir, tenofovir and lamivudine. Since then
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her thrombocyte count remained stable and
above 160 × 109/l. Her viral load dropped be-
low 40,000 copies/ml plasma but remained above
5000 copies/ml plasma because of multidrug resis-
tance.
This patient developed severe thrombocytope-
nia on challenge-rechallenge with indinavir and
lopinavir/ritonavir. Other causes of thrombocytope-
nia, such as cancer or renal failure, were not found.
Since her ﬁrst admission to the hospital she had not
used IV drugs or other narcotics. She presented with
mild chronic autoimmune HIV-associated thrombo-
cytopenia before HIV treatment was started. Each
time indinavir or lopinavir/ritonavir was introduced
a further decrease of the platelet count together
with a decrease of the viral loadwas observed. Once
the protease inhibitors were stopped we observed
a rise in the platelet count together with a rise in
viral load. If the thrombocytopenia was only caused
by the HIV infection itself the reverse would be ex-
pected: an increase in platelet count when the viral
load is decreasing and a decreasing platelet count
when the viral load is increasing. Indinavir-induced
thrombocytopenia has been described in the past
in three patients with pre-existing mild autoim-
mune HIV-associated thrombocytopenia.8—10 As far
as we know, our patient is the ﬁrst reported case
of thrombocytopenia caused by lopinavir/ritonavir
treatment.
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